A Long-Term Extension Study to Evaluate Safety and Efficacy of Verekitug (UPB-101) in Adult Participants With Severe Asthma Who Completed the VALIANT Trial
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
- Upstream Bio Inc.
- Enrollment
- 396
- Locations
- 153
- Primary Endpoint
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Study Overview
Brief Summary
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Completion of the VALIANT study (UPB-CP-04 [NCT06196879]) per protocol.
- •Participant has signed, dated, and received a copy of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) for the LTE study.
- •Contraceptive use by participants must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria
- •Abnormal medical history, physical finding, or safety finding that in the opinion of the Investigator may obscure the study data or interfere with the participant's safety.
- •Any clinical laboratory test result outside of the reference ranges considered by the Investigator as clinically significant and that may obscure the study data or interfere with the participant's safety.
- •Participant with a history or evidence of a clinically significant pulmonary condition (other than asthma), including significant restrictive findings on pulmonary function testing, chronic bronchitis, emphysema, bronchiectasis, pulmonary fibrosis, or any other related condition that may obscure the study data (e.g., gastroesophageal reflux and vocal cord paralysis/dysfunction).
- •Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study or unwilling to use adequate birth control, if of reproductive potential and sexually active.
- •Participants with significant protocol deviations in VALIANT, assessed at the discretion of the Sponsor.
- •Participant is unreliable, incapable of adhering to the protocol and visit schedule according to the judgment of the Investigator or has any disorder that may compromise their ability to give informed consent.
Arms & Interventions
Verekitug 400 mg Q24W and Placebo
Participants will receive 2.0 mL of verekitug (400 mg) and 0.5 mL of matching placebo, SC injections, at Weeks 24 and 48 visits. Participants will also receive 2.0 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.
Intervention: Verekitug (Drug)
Verekitug 100 mg Q12W and Placebo
Participants will receive 0.5 mL of verekitug (100 mg) and 2.0 mL of matching placebo, subcutaneous (SC) injections, every 12 weeks (Q12W) for up to 48 weeks.
Intervention: Placebo (Drug)
Verekitug 100 mg Q12W and Placebo
Participants will receive 0.5 mL of verekitug (100 mg) and 2.0 mL of matching placebo, subcutaneous (SC) injections, every 12 weeks (Q12W) for up to 48 weeks.
Intervention: Verekitug (Drug)
Verekitug 400 mg Q24W and Placebo
Participants will receive 2.0 mL of verekitug (400 mg) and 0.5 mL of matching placebo, SC injections, at Weeks 24 and 48 visits. Participants will also receive 2.0 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From VALOUR baseline up to Week 64
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Secondary Outcomes
- Annualized Asthma Exacerbation Rate (AAER)(From VALOUR baseline up to Week 60)
- Change from LTE Baseline in Forced Expiratory Volume in 1 Second (FEV1)(From VALOUR baseline to Week 60)
- Change from LTE Baseline in Fractional Exhaled Nitric Oxide (FeNO)(From VALOUR baseline up to Week 60)
- Change from LTE Baseline in Asthma Control Questionnaire-6 (ACQ-6)(From VALOUR baseline to Week 60)